Literature DB >> 15838642

Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast.

Peter J Barth1, Roland Moll, Annette Ramaswamy.   

Abstract

In the present study, we analyzed tumor associated stromal remodeling with special respect to SPARC (secreted protein acid rich in cysteine) expression. 25 invasive ductal carcinomas of the breast and corresponding tumor-free breast tissue were studied immunohistochemically (CD34, alpha-SMA, SPARC and TGFbeta-R1). Tumor associated stroma was characterized by a loss of CD34 expression, paralleled by a gain in alpha-SMA. While SPARC expression was virtually absent from normal stromal cells in the tumor stroma, strong cytoplasmic SPARC reactivity was found in the majority of stromal cells. The TGFbeta-R1 also showed stronger expression in the tumor stroma compared to that of the normal breast. Stromal response to antecedent core needle biopsy was similar to that observed in the tumor stroma. We conclude that SPARC overexpression is a constant and functionally important feature of invasive ductal carcinomas, since SPARC mediates stromal de-adhesion crucial for local tumor invasion and systemic spread, respectively. When considering changes of the stromal phenotype (normal: CD34+alpha-SMA-SPARC- vs. carcinoma: CD34-alpha-SMA+SPARC+) as a tool in distinguishing benign from malignant breast lesion one has to keep in mind that the phenotype of granulation tissue in areas of antecedent biopsy resembles that of tumor stroma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15838642     DOI: 10.1007/s00428-005-1256-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  27 in total

1.  SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system.

Authors:  Barbara J Schiemann; Jason R Neil; William P Schiemann
Journal:  Mol Biol Cell       Date:  2003-06-27       Impact factor: 4.138

2.  The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ.

Authors:  J Chesney; M Bacher; A Bender; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  CD34 positive stromal cells in gastric adenocarcinomas.

Authors:  H Nakayama; H Enzan; E Miyazaki; N Kuroda; K Naruse; H Kiyoku; M Toi; M Hiroi
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

4.  Differential expression of CD34 in normal colorectal tissue, peritumoral inflammatory tissue, and tumour stroma.

Authors:  H Nakayama; H Enzan; E Miyazaki; N Kuroda; K Naruse; M Hiroi
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

5.  CD34+ fibrocytes in neoplastic and inflammatory pancreatic lesions.

Authors:  Peter J Barth; Schokufe Ebrahimsade; Achim Hellinger; Roland Moll; Annette Ramaswamy
Journal:  Virchows Arch       Date:  2002-02       Impact factor: 4.064

6.  The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types.

Authors:  Christine A Iacobuzio-Donahue; Pedram Argani; Paula M Hempen; Jessa Jones; Scott E Kern
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

7.  CD-34 expression by cultured human keratocytes is downregulated during myofibroblast differentiation induced by TGF-beta1.

Authors:  Edgar M Espana; Tetsuya Kawakita; Chia-Yang Liu; Scheffer C G Tseng
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-09       Impact factor: 4.799

8.  Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.

Authors:  Roderick J Phillips; Marie D Burdick; Kurt Hong; Marin A Lutz; Lynne A Murray; Ying Ying Xue; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

9.  Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma.

Authors:  Matthias Schmidt; Guo Sun; Martin A Stacey; Luca Mori; Sabrina Mattoli
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

10.  TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors.

Authors:  M J Reed; R B Vernon; I B Abrass; E H Sage
Journal:  J Cell Physiol       Date:  1994-01       Impact factor: 6.384

View more
  21 in total

Review 1.  Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review.

Authors:  Sepanta Hosseinpour; Fatemeh Mashhadiabbas; Mitra Ghazizadeh Ahsaie
Journal:  Pathol Oncol Res       Date:  2016-12-06       Impact factor: 3.201

2.  CD34+ fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder.

Authors:  Wilhelm Nimphius; Roland Moll; Peter Olbert; Annette Ramaswamy; Peter J Barth
Journal:  Virchows Arch       Date:  2007-02       Impact factor: 4.064

3.  In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression.

Authors:  Nah Ihm Kim; Ga-Eon Kim; Ji Shin Lee; Min Ho Park
Journal:  Virchows Arch       Date:  2016-12-01       Impact factor: 4.064

4.  CD34(+) fibrocytes in melanocytic nevi and malignant melanomas of the skin.

Authors:  Cordula Wessel; Christina C Westhoff; Katharina Nowak; Ingrid Moll; Peter J Barth
Journal:  Virchows Arch       Date:  2008-09-24       Impact factor: 4.064

5.  Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer.

Authors:  Jian-fang Liang; Hong-kun Wang; Hong Xiao; Ning Li; Cai-xia Cheng; Yu-ze Zhao; Yan-b Ma; Jian-zhong Gao; Rui-bing Bai; Hui-xia Zheng
Journal:  J Exp Clin Cancer Res       Date:  2010-06-16

6.  The fibromatosis signature defines a robust stromal response in breast carcinoma.

Authors:  Andrew H Beck; Inigo Espinosa; C Blake Gilks; Matt van de Rijn; Robert B West
Journal:  Lab Invest       Date:  2008-04-14       Impact factor: 5.662

7.  A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.

Authors:  Lindsay B Alcaraz; Aude Mallavialle; Timothée David; Danielle Derocq; Frédéric Delolme; Cindy Dieryckx; Caroline Mollevi; Florence Boissière-Michot; Joëlle Simony-Lafontaine; Stanislas Du Manoir; Pitter F Huesgen; Christopher M Overall; Sophie Tartare-Deckert; William Jacot; Thierry Chardès; Séverine Guiu; Pascal Roger; Thomas Reinheckel; Catherine Moali; Emmanuelle Liaudet-Coopman
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

8.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

9.  Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast.

Authors:  Xavier Catteau; Philippe Simon; Michel Vanhaeverbeek; Jean-Christophe Noël
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

Review 10.  Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis.

Authors:  G S Wong; A K Rustgi
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.